Cargando…

Dopamine Agonist Therapy in Advanced Parkinson’s Disease

Detalles Bibliográficos
Autor principal:	Reichmann, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Movement Disorder Society 2009
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027692/ https://www.ncbi.nlm.nih.gov/pubmed/24868345 http://dx.doi.org/10.14802/jmd.09003

Ejemplares similares

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy
por: Sampaio, Tuane Bazanella, et al.
Publicado: (2017)

Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology
por: Borovac, Josip Anđelo
Publicado: (2016)

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
por: Frazer, Monica, et al.
Publicado: (2022)

Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2014)

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease
por: Castro, Ester Suárez, et al.
Publicado: (2016)

Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
por: Merseburger, Axel S., et al.
Publicado: (2014)

Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
por: Kim, Jong-Min, et al.
Publicado: (2015)

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
por: Zhang, Jinglin, et al.
Publicado: (2016)

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease
por: Picillo, Marina, et al.
Publicado: (2020)

Dopamine Agonist-Associated Hiccup in Parkinson’s Disease: A Case Report
por: EMEKLİ, Ahmed Serkan, et al.
Publicado: (2019)

The Epigenome as a therapeutic target for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2016)

On the role of endogenous neurotoxins and neuroprotection in Parkinson's disease
por: Segura-Aguilar, Juan
Publicado: (2017)

Neural grafting for Parkinson's disease: challenges and prospects
por: Stoker, Thomas B., et al.
Publicado: (2017)

Drug repurposing strategies of relevance for Parkinson’s disease
por: Fletcher, Edward J. R., et al.
Publicado: (2021)

Neuroinflammation in Parkinson’s Disease and its Treatment Opportunities
por: Çınar, Elif, et al.
Publicado: (2022)

Therapeutic potential of α7 nicotinic receptor agonists to regulate neuroinflammation in neurodegenerative diseases
por: Foucault-Fruchard, Laura, et al.
Publicado: (2017)

Tracking of iron-labeled human neural stem cells by magnetic resonance imaging in cell replacement therapy for Parkinson's disease
por: Ramos-Gómez, Milagros, et al.
Publicado: (2016)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
por: Isaacson, Stuart H., et al.
Publicado: (2023)

MicroRNAs in Parkinson's disease and emerging therapeutic targets
por: Martinez, Bridget, et al.
Publicado: (2017)

The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease
por: Kinghorn, Kerri J., et al.
Publicado: (2017)

Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson’s Disease
por: Jing, Xiao-Zhong, et al.
Publicado: (2023)

The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson’s disease: an observational study
por: Pellicano, Clelia, et al.
Publicado: (2013)

The treatment of Parkinson's disease with deep brain stimulation: current issues
por: Moldovan, Alexia-Sabine, et al.
Publicado: (2015)

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Compulsive Drumming Induced by Dopamine Agonists in Parkinson’s Disease: Another Aspect of Punding
por: Vitale, Carmine, et al.
Publicado: (2013)

No Dopamine Agonist Modulation of Brain [(18)F]FEOBV Binding in Parkinson’s Disease
por: Albin, Roger L., et al.
Publicado: (2022)

New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases
por: Hölscher, Christian
Publicado: (2014)

Olfactory Loss in Parkinson's Disease
por: Haehner, Antje, et al.
Publicado: (2011)

Dopamine Receptors and Parkinson's Disease
por: Hisahara, Shin, et al.
Publicado: (2011)

Translating the promise of 5HT(4) receptor agonists for the treatment of depression
por: Murphy, Susannah E, et al.
Publicado: (2021)

Treatment of Parkinson’s disease in the advanced stage
por: Ossig, C., et al.
Publicado: (2013)

Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-Synuclein
por: Béraud, Dawn, et al.
Publicado: (2012)

Natural polyphenols effects on protein aggregates in Alzheimer's and Parkinson's prion-like diseases
por: Freyssin, Aline, et al.
Publicado: (2018)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Role of dopamine in the pathophysiology of Parkinson’s disease
por: Zhou, Zhi Dong, et al.
Publicado: (2023)

Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification
por: Lauterbach, Edward C.
Publicado: (2016)

TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease
por: Binukumar, BK, et al.
Publicado: (2016)

Prevalence of hypersexual behavior in Parkinson’s disease patients: Not restricted to males and dopamine agonist use
por: Cooper, Christine A, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_8pjsiaos4d81jf01ontmsggall